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Purpose: While there are many known etiologies of choroidal neovascularization (CNV), tuberculosis is
not a well-known causative agent. In this case series, we highlight CNV occurring secondary to tuber-
culous chorioretinitis, its presentation, and its management.
Observations: We retrospectively reviewed the charts and imaging of four patients who presented with
presumed tuberculous chorioretinitis and CNV. Three of these patients had signs of intraocular inﬂam-
mation and were also found to have active macular CNV. The one remaining patient had chorioretinal
scars from prior posterior uveitis and previously treated macular CNV membranes. The three patients
with active disease were started on anti-tuberculosis medications and oral corticosteroids, and they also
received intravitreal anti-vascular endothelial growth factor (VEGF) injections as needed for the CNV.
There was a signiﬁcant improvement in the clinical course of all three patients with active diseasedthe
intraocular inﬂammation subsided, and CNV recurrences were mitigated. Upon completion of systemic
treatment, all patients have remained quiescent.
Conclusions and importance: Our ﬁndings demonstrate that CNV may occur in the course of tuberculous
chorioretinitis with marked loss of vision, and management with anti-tuberculosis medications, oral
corticosteroids, and intravitreal anti-VEGF injections results in notable improvement in their clinical
course.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Choroidal neovascularization (CNV) may lead to signiﬁcant vi-
sual morbidity when left untreated. There are multiple known
causes of CNV. Broadly, the categories include degenerative con-
ditions (age-related macular degeneration, pathologic myopia,
angioid streaks), hereditary degenerative conditions (vitelliform
macular dystrophy), inﬂammatory conditions (ocular histo-
plamosis syndrome, multifocal choroiditis), infectious etiologies
(toxoplasmosis), tumors, traumatic, and idiopathic. Elucidating the
underlying etiology of a CNV membrane (CNVM) is important for
determining the treatment and prognosis of the eye.
Tuberculosis (TB) is overall an uncommon etiology for CNV,
which is driven by vascular endothelial growth factor (VEGF).
However, experimental animal models of intraocular TB reveal
VEGF expression in the RPE, which has been shown to harbor
Mycobacterium tuberculosis that thrive by inhibiting phag-
olysosome fusion.1e3 In this case series, we highlight four patients
who developed CNV with tuberculous chorioretinitis and describe
their subsequent management.
2. Findings
2.1. Case 1
A 57-year-old Korean female was diagnosed with “tuberculous
uveitis” in both eyes (OU) by an outside ophthalmologist based on a
positive tuberculin skin test and interferon-gamma release assay.
* The authors have not published or submitted any related papers from this
study.
* Corresponding author.
E-mail addresses: kim.esther.lee@gmail.com (E. Lee Kim), damien.rodger@med.
usc.edu (D.C. Rodger), narsing.rao@med.usc.edu (N.A. Rao).
1 Current address: 243 Charles Street Boston, MA, 02114, USA.
Contents lists available at ScienceDirect
American Journal of Ophthalmology Case Reports
journal homepage: http: / /www.ajocasereports .com/
http://dx.doi.org/10.1016/j.ajoc.2016.12.025
2451-9936/© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
American Journal of Ophthalmology Case Reports 5 (2017) 124e129
The patient was started on quadruple anti-tuberculosis therapy and
oral prednisone 10mg daily, but pyrimethamine and ethambutol
were discontinued after two weeks due to intolerable side effects.
The patient received an intravitreal triamcinolone injection in the
left eye (OS) for distorted central vision.
Three months later, she presented with a best-corrected visual
acuity (BCVA) of 20/30 in the right eye (OD) and 20/40 OS. Exam
was notable for vitritis OU, macular CNV, subretinal tissue, cystoid
edema, and peripheral chorioretinal scars OS (Fig. 1). Fluorescein
angiography (FA), optical coherence tomography (OCT), and
indocyanine green revealed a Type 1 choroidal neovascular mem-
brane (CNVM) parafoveally OS (Fig. 1). Autoﬂuorescence (AF) was
notable for peripapillary hypoautoﬂuorescence with hyper-
ﬂuorescence at the edges of the chorioretinal lesions OS. The pa-
tient was continued on anti-tuberculosis therapy and
corticosteroids. After three intravitreal bevacizumab injections
with persistent sub- and intraretinal ﬂuid OS, the patient was
switched to aﬂibercept with notable improvement. Six weeks later,
the ﬂuid recurred, and the patient's oral prednisone was increased
to 20mg daily for one week, followed by 15mg daily thereafter.
There was a slight improvement in the macular edema, and after
nine months of anti-tuberculosis treatment with an ongoing oral
prednisone taper, the patient has remained quiescent.
2.2. Case 2
A 76-year-old Indian male with rheumatoid arthritis on meth-
otrexate was referred for “tuberculous serpiginoid chorioretinitis”
diagnosed two years ago based on a positive interferon-gamma
release assay. The patient underwent triple anti-tuberculosis ther-
apy for six months, after which he developed CNV OS then OD. He
Fig. 1. Case 1. a) Wide-ﬁeld optos fundus photo of the left eye is notable for peripapillary subretinal tissue hypopigmented chorioretinal lesions. b) Optical coherence tomography of
the left eye demonstrating macular, subretinal tissue, and cystoid macular edema. c, d) Fluorescein angiogram of the left eye with mid (C) and late (d) phase images, respectively,
demonstrating peripapillary staining and leakage. eeg) Indocyanine green angiogram of the left eye with early (e), mid (f), and late (g) phase images from left to right. There is an
area of juxtapapillary leakage in the nasal macula. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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received multiple intravitreal bevacizumab injections OU with
limited response.
Upon referral, the patient's BCVAwas 20/100 OD and 20/200 OS.
Examination revealed vitritis and scattered hypopigmented cho-
rioretinal scars throughout themacula and periphery OU (Fig. 2). AF
and FA showed active inﬂammation OU and a large macular CNVM
OS. OCT revealed Type 2 choroidal neovascularization and exten-
sive subretinal ﬁbrosis. Because of concern for resistant mycobac-
teria, the patient was placed on quadruple therapy and oral
prednisone 20mg daily and received an intravitreal bevacizumab
injection OS. After six months of anti-tuberculosis treatment and
continuing on a slow prednisone taper, there persisted an area of
Fig. 2. Case 2. a, b) Fundus photos of the right (a) and left (b) eyes demonstrate serpiginoid hypopigmented chorioretinal lesions in both eyes. c) Autoﬂuorescence of the left eye
reveals hypoautoﬂuorescence of the chorioretinal lesions with hyperautoﬂuorescence at the lesion edges. (d) Late-phase ﬂuorescein angiography of the left eye shows peripapillary
staining and a large area of macular leakage corresponding to choroidal neovascularization. e) Optical coherence tomography of the left eye is notable for dense subretinal ﬁbrosis
and hemorrhage consistent with Type 2 choroidal neovascularization.
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subretinal ﬂuid OS. Given the poor visual potential and lack of
active inﬂammation, the patient elected to observe.
2.3. Case 3
A 39-year-old Vietnamese female without past medical history
who immigrated to the United States at an early age presented
complaining of a “blind spot” and photopsias OD for three weeks.
She reported a similar blind spot OS which never resolved. On
initial presentation, BCVA was 20/30 OU. Examination revealed
trace vitritis OU, hypopigmented peripapillary lesions OD, and
scattered old chorioretinal scars OS (Fig. 3). FA did not demonstrate
any leakage. Based on a positive tuberculin skin test, she was
diagnosed with tuberculous multifocal choroiditis and started on a
nine-month course of triple therapy and oral prednisone 40mg
daily. Ethambutol was discontinued two weeks later due to dizzi-
ness and nausea. The intraocular inﬂammation subsequently sub-
sided, but six months into the course of treatment, macular CNV
developed OD (Fig. 3). This responded well to a single intravitreal
bevacizumab injection, after which she received two more as a
loading dose.
Four years later, she developed intermittent CNVMs OU, which
were treated with bevacizumab eight times OD and two times OS.
New active chorioretinal lesions were seen on autoﬂuorescence OU,
and the patient was re-started on rifampin, isoniazid, and oral
prednisone 40mg daily. Anti-VEGF injections were switched to
aﬂibercept, of which she received four injections OD and two OS.
After completing one year of anti-tuberculosis therapy, the patient
has since remained quiescent with BCVA 20/30 OU.
2.4. Case 4
A 65 year-old Indian male with history of a positive tuberculin
skin test in 1986 for which he underwent one year of quadruple
therapy presented with a history of tuberculous chorioretinitis OU.
Based on review of outside records, the patient had developed a
recurrent macular CNVM OS for which he received ﬁve ranibizu-
mab injections, most recently two years ago. On presentation, BCVA
was hand motions OD and 20/100 OS. Exam was notable for
extensive subretinal scars, chorioretinal atrophy, and pigmentary
changes OD greater than OS (Fig. 4). There was currently no evi-
dence of active uveitis on evaluation, and OCT images did not
demonstrate the presence of subretinal or intraretinal ﬂuid. He has
remained quiescent for the past year.
3. Discussion
TB chorioretinitis likely develops as an exuberant immune
response to reactivation of dormant Mycobacterium tuberculosis
harbored in the RPE.2,3 Similarly, choroidal seeding secondary to
reactivation elsewhere in the body may also lead to intraocular TB
inﬂammation.1 Experimental animal models of ocular TB reveal
localized tissue hypoxia and enhanced VEGF levels at foci of TB
infections,4 which may account for the occurrence of CNV in cases
of tuberculous uveitis.
The earliest mention of TB-associated CNV in the literature was
in a 1987 case report, where “subretinal neovascularization”
occurred 34 years after the initial TB diagnosis and was treated
successfully with isoniazid and laser photocoagulation.5
Several therapeutic strategies have been attempted for uveitis-
related CNV: focal laser photocoagulation,6 photodynamic ther-
apy with verteporﬁn,7 local and systemic corticosteroids,8 systemic
immunosuppression,9 surgery,10 and most recently, intravitreal
bevacizumab injections.11,12 Given the elevated VEGF levels asso-
ciated with intraocular TB infections, anti-VEGF therapy may
effectively suppress TB-related CNV.4
In a study by Julian et al., 15 patients with CNV secondary to
uveitis, including one tuberculous uveitis, received intravitreal
Fig. 3. Case 3. a, b) Fundus photos of the right (a) and left (b) eyes demonstrate well-demarcated peripapillary hypopigmented chorioretinal lesions. cee) Fluorescein angiogram of
the right eye with early (a), mid (b), and late (c) phase images reveals an area of leakage nasal to the fovea with staining at the peripapillary chorioretinal scars.
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bevacizumab injections for CNV treatment.11 After 17 months
follow-up, nearly 80% of eyes showed signiﬁcant improvement in
visual acuity and OCT macular thickness after a mean 4.25 in-
jections. However, most patients had been started on systemic
immunosuppressive agents prior to initiation of bevacizumab,
which included intravenous methylprednisolone pulse therapy,
oral prednisone (~1mg/kg/day), azathioprine, and interferon alpha.
The authors suggested that systemic immunosuppression is critical
for targeting the underlying inﬂammatory process.
One cannot overlook the multiple deleterious side effects
associated with immunosuppressive agents, which further com-
pound the potential hepatotoxicity of anti-tuberculosis medica-
tions. In light of this, we recommend treating TB-related CNV with
intravitreal anti-VEGF injections coupled with systemic anti-
Fig. 4. Case 4. a) Wide-ﬁeld Optos fundus photo of the right eye demonstrating extensive chorioretinal atrophy and retinal pigment epithelial migration. b) Fundus photo of the left
eye has a similar but less extensive appearance of peripapillary chorioretinal atrophy and pigmentary changes. c) Autoﬂuorescence demonstrates hypoautoﬂuorescence at the area
of chorioretinal atrophy. d) Optical coherence tomography of the left eye reveals subretinal ﬁbrosis without subretinal or intraretinal ﬂuid.
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tuberculosis medications and oral corticosteroids. Failed efﬁcacy of
intravitreal bevacizumab leads one to consider other anti-VEGF
agents such as aﬂibercept, as we describe the earliest use of this
newer agent with CNV due toTB uveitis. It is important to recognize
CNV as a potential sequelae of TB chorioretinitis to ensure proper
management with both local and systemic agents.
4. Conclusions
This retrospective case series highlights four patients presenting
with active choroidal neovascularization or prior choroidal neo-
vascular membranes as a result of tuberculous chorioretinitis. The
three patients with active choroidal neovascular membranes were
all treated with anti-tuberculosis medications and oral corticoste-
roids, in addition to anti-VEGF injections. Intravitreal aﬂibercept
was found to be particularly efﬁcacious, and we describe the
earliest use of this newer agent in these cases. All three patients had
a notable improvement in their clinical course with retention of
their baseline visual acuity. This study emphasizes the importance
of identifying tuberculosis as a cause of choroidal neo-
vascularization to ensure proper management of these patients
with a combination of local and systemic therapy.
5. Patient consent
The Institutional Review Board at USC approved the study
protocol, and all participants provided written consent for inclu-
sion in this study.
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